References
- Weinberg PB, Becker S, Granger DL, Koren HS. Growth inhibition of Ctyptococcus neoformans by human alveolar macrophages. Am Rev Respir Dis 1987; 136: 1242–1247.
- Miller MF, Mitchell TG. Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun 1991; 59: 24–28.
- Karaoui, RM, Hall, NK, Larsh, HW. Role of macrophages in immunity and pathogenesis of experimental cryptococcosis induced by the airborne route. II. Phagocytosis and intracellular fate of Cryptococcus neoformans. Mykosen 1977; 20: 409–422.
- Levitz SM, Farrell TP, Maziarz RT. Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. J Infect Dis 1991; 163: 1108–1113.
- Nassar F, Brummer E, Stevens DA. Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronch-°alveolar and peritoneal macrophages against Cryptococcus neoformans. Antimicrob Agents Chemot her 1994; 38:2162–2164.
- Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998; 102: 663–670.
- Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activityof a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998; 36: 433–436.
- Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999; 43: 169–171.
- Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663–665.
- Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42:907–910.
- Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42: 2299–2303.
- Levitz SM. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect Immun 1991; 59: 3393–3397.
- Chen GH, Curtis JL, Mody CH, et aL Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macro-phage anticryptococcal activity in vitro. J Immunol 1994; 15/ 724–734.